相关实验视频
Updated: Jan 11, 2026

08:54
Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
Published on: February 17, 2023
1.5K
外源/内源刺激反应的抗瘤前期药物提前精确化疗
Luo Wang1, Jingao Li1, Xuanwei Zeng1
1State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
Bioorganic & medicinal chemistry
|November 18, 2025
概括
刺激反应性前药物通过使用外部或内部触发器来激活药物只在瘤部位提供精确化疗. 这种方法最大限度地减少了副作用,并提高了治疗效率,以获得更好的癌症治疗.
科学领域:
- 在瘤学瘤学.
- 药物运输 药物运输 药物运输
- 生物医学工程 生物医学工程
背景情况:
- 传统化疗面临的挑战是异于目标的毒性,影响健康细胞.
- 精密化疗旨在选择性地向癌细胞,改善治疗结果.
- 对刺激有反应的前药物代表了显著的进步,使向药物激活成为可能.
研究的目的:
- 审查刺激反应性抗瘤前期药物的最新进展.
- 分析设计原则,激活机制和治疗疗效.
- 突出这些前药物在增强癌症治疗中的潜力.
主要方法:
- 对外源刺激反应的前药物 (光,辐射,超声波) 的分析.
- 对内源性刺激反应前药物 (低氧,pH,酶,ROS,GSH) 的分析.
- 专注于前药物设计,触发机制和临床疗效.
主要成果:
- 外源刺激提供时空精度,减少系统性副作用.
- 内源刺激利用瘤微环境进行选择性药物激活.
- 产物药物经历特定的反应,在目标部位释放活性剂.
结论:
- 刺激反应性前药物提高了治疗疗效和癌症治疗中的安全性.
- 这些策略为更精确,更有效的化疗铺平了道路.
- 有针对性的药物激活可以最大限度地减少对健康组织的损伤,从而改善患者的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Prodrugs
3.8K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
3.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
527
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
527

